FDA Granted Breakthrough Status to Medtronic BTK Device

The designation covers a specialized catheter designed to treat patients facing severe peripheral artery disease.

Updated on Oct. 1, 2026 in Stroke

FDA Granted Breakthrough Status to Medtronic BTK Device

Live Poll

Should the FDA fast-track breakthrough medical devices to treat life-threatening conditions?

The FDA has granted breakthrough device designation to Medtronic for its In.Pact BTK catheter, a tool designed to treat peripheral artery disease. The technology utilizes a paclitaxel delivery system to help patients manage risks associated with critical limb-threatening ischemia.

Why it matters

Currently, no drug-coated balloons are commercially available in the U.S. for lesions located below the knee, making this device a potential solution for patients facing high risks of major amputation or death.

The planned pivotal trial for the In.Pact BTK device aims to enroll approximately 400 participants with peripheral artery disease. The previous In.Pact AV fistula study reported a target lesion primary patency rate of 70.2%.

The players

Medtronic

Medtronic is a global medical technology company that develops devices and solutions for various chronic conditions.

FDA

The FDA is a federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices and drugs.

Abbott

Abbott is a diversified healthcare company that manufactures a wide range of medical devices, diagnostic tests, and nutritional products.

The details

The catheter works by delivering a formulation of paclitaxel directly to the vessel to inhibit the growth of scar tissue. This approval follows Medtronic’s 2017 feasibility study and marks a significant step toward addressing treatment gaps for patients suffering from critical limb-threatening ischemia.

Medtronic launched an initial feasibility study for the device in 2017.
The FDA approved Abbott's Esprit BTK drug-eluting scaffold in July 2026.
Medtronic received breakthrough designation for the In.Pact BTK catheter on October 1, 2026.
The pivotal trial design is expected to be finalized within the next few months.

Healthcare
Sept. 29
CMS Removed Medicare Pathways for Breakthrough Devices
Stroke
Sept. 24
Perfuze Catheter Outperformed Rivals in Bench Study
Robotics
Sept. 28
FDA Authorized Johnson & Johnson Surgical Robot

Health Landscape

This development reflects a broader industry shift toward improving treatment outcomes for patients with critical limb-threatening ischemia. Medtronic’s progress follows the regulatory approval of Abbott's Esprit BTK drug-eluting scaffold, further expanding the options for specialized vascular care.

This breakthrough designation signifies a potential expansion in future treatment options for patients at high risk of amputation due to peripheral artery disease. As the pivotal trial progresses, it brings the technology one step closer to clinical availability for those requiring below-the-knee interventions.

The takeaway

The FDA designation represents a critical milestone in the development of drug-coated technologies for complex vascular conditions. Patients and providers should monitor upcoming trial results as they will determine the efficacy and future accessibility of this treatment.

What happens next

Medtronic plans to finalize the design for its international, randomized pivotal trial within the next few months to begin the study involving approximately 400 participants.